Report on an engineered enzyme that removes a common advanced glycation modification from aged human tissues ex vivo, reframing repair possibilities for molecular damage.
Key Takeaways
- Researchers studying aging have largely viewed advanced glycation end products (AGEs)
- While efforts have focused on slowing their formation or limiting their downstream effects
- Yet dismissing the study on those grounds would miss the point entirely